IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 6006 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   [PDF Not available] *
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   Abstract
   Introduction
   Meterials and Me...
   Results
   Discussion
   Acknowledgment
   References

 Article Access Statistics
    Viewed5929    
    Printed75    
    Emailed1    
    PDF Downloaded0    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 


 
SHORT COMMUNICATION
Year : 1995  |  Volume : 61  |  Issue : 4  |  Page : 212-213

Ciprofloxacin therapy in chronic folliculitis of legs




Correspondence Address:
C Balachandran


Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 20952957

Rights and PermissionsRights and Permissions

  Abstract 

The efficacy of ciprofloxacin was evaluated in 25 patients with chronic folliculitis of legs in a double-blind cross over study. Though ciprofloxacin was found to be far more effective than the placebo the average remission time was only 44.5 days


Keywords: Ciprofloxacin, Chronic folliculitis of legs


How to cite this article:
Balachandran C, Malpani S, Srinivas C R. Ciprofloxacin therapy in chronic folliculitis of legs. Indian J Dermatol Venereol Leprol 1995;61:212-3

How to cite this URL:
Balachandran C, Malpani S, Srinivas C R. Ciprofloxacin therapy in chronic folliculitis of legs. Indian J Dermatol Venereol Leprol [serial online] 1995 [cited 2019 Nov 18];61:212-3. Available from: http://www.ijdvl.com/text.asp?1995/61/4/212/4210



  Introduction Top


Chronic folliculitis of the legs (CFL) has been described mainly in young adult males in India. Staphylococcus aureus has been isolated from most of the lesions. Treatment of CFL is frustrating to both physicians and the patients. Various antibiotics has been tried in the treatment of CFL but recurrence of the disease is usually seen.[1],[2] Ciprofloxacin, a fluoroquinolone antimicrobial agent, which is known to be active against a broad spectrum of gram +ve and gram -ve bacteria, was tried in the treatment of this recalcitrant condition.


  Meterials and Methods Top


25 clinically diagnosed cases of CFL were studied. Lesions were graded into 3 categories according to the extent of involvement. Aggravating factors, scarring and other associated findings were noted. In vitro culture and sensitivity of the pus from the lesion was done in all cases prior to therapy. Patients at random received either ciprofloxacin twice daily or colour and size-matched placebo twice daily. Both the drugs were coded by Ranbaxy Pharmaceuticals, New Delhi. After one week, if there was no clinical improvement, the drug was discontinued and treatment was continued with the other drug for another 2 weeks. Hence, the patient himself acted as his own control. Clinical improvement was recorded at the end of 2nd week by grading the lesions. Patients were followed up every 4 weeks till 24 weeks. The drugs were decoded after the completion of the study.


  Results Top


Out of a total of 25 patients, 22 were male and 3 were female. They had a wide range of occupation. 25% were agriculturists and 20% were students. 84% petients had Grade III lesions (more than 10 pustules). Coagulase + ve staphylococci were grown in culture in 88% of the patients.

Placebo was received by 13 patients at random as the first drug. Of these, 2 patients showed complete disappearance of the lesions, while in the remaining 11 there was no clinical improvement. Later 2 patients who failed to show any clinical improvement with ciprofloxacin as the first drug were also given placebo, but no improvement of the disease was seen. Ciprofloxacin was given randomly as the first drug to a total of 12 patients, of which 10 improved. 11 patients who failed to respond to placebo were then given ciprofloxacin following which all improved. Thus out of a total of 23 patients who received ciprofloxacin, 21 patients improved.

Out of the study group of 25 patients, 21 patients [84%] improved with ciprofloxacin, 2 patients [8%] improved with placebo while remaining 2 patients [8%] failed to show any improvement with either ciprofloxacin or placebo. The average remission period was 44.5 days with ciprofloxacin, while that of 2 patients improved with placebo was 40 days. There were no untoward side effects with the drugs.


  Discussion Top


Ciprofloxacin is effective by mouth, side effects are few and bacterial resistance is less. The primary target of ciprofloxacin is the bacterial enzyme, DNA gyrase, which is essential for the DNA synthesis.[3],[4]

Though ciprofloxacin was far more effective than placebo (P<0.01) the average remission time was only 44.5 days. There are not many reports regarding efficacy of this drug in CFL, neither there was any proper follow up study to determine the remission period. Ciprofloxacin was found to be effective in skin infections caused by staphylococci.[5][6][7] The improvement noticed in 2 patients with placebo could be attributed to various other factors like alteration of the occupation, use of soaps or psychology of the patient.

Thus, it can be concluded that ciprofloxacin, though effective, cannot be regarded as superior to other conventional antibiotics like erythromycin, cotrimoxazole etc. in bringing a long-lasting remission to this malady. The gates for an effective management of this frustrating condition CFL are still open.


  Acknowledgment Top


Sincere thanks to Ranbaxy Laboratories for providing the drug and the placebo.

 
  References Top

1.Desai SC, Shah BH, Mody PJ, et al. Therapy resistant pyogenic folliculitis on legs in adult males with hyper gammaglobulinaemia. Ind J Dermatol Venereol 1964;30:89-97.  Back to cited text no. 1    
2.Sugathan P, Zachariah J, Joy MI. Folliculitis cruris pustulosa et atrophicans. Ind J Dermatol Venereol 1973;39:35-40.  Back to cited text no. 2    
3.Neu HC. Ciprofloxacin-An overview and prospective appraisal. Am J Med 1987;82(Suppl 4A):395-404.  Back to cited text no. 3    
4.Hooper DC, Wolfson JS, NG EY, et al. Mechanism of action of and resistance to ciprofloxacin. Am J Med 1987;82(Suppl 4A):12-20.  Back to cited text no. 4    
5.James DJ. Therapeutic focus, the fluoroquinolones. Br J Clin Pract 1989;43:66-7.  Back to cited text no. 5    
6.Barry AL, Jones RN. In vitro activity of ciprofloxacin against gram - positive cocci. Am J Med 1987:82 (Suppl 4A):27-32.  Back to cited text no. 6    
7.Valainis GT, Pankey GA, Katner HP, et al. Ciprofloxacin in the treatment of bacterial skin infection. Am J Med 1987;82(Suppl 4A):230-32.  Back to cited text no. 7    



This article has been cited by
1 Dermatitis cruris pustulosa et atrophicans revisited: Our experience with 37 patients in south India
Kaimal, S., DęSouza, M., Kumari, R., Parija, S.C., Sistla, S., Badhe, B.A.
International Journal of Dermatology. 2009; 48(10): 1082-1090
[Pubmed]
2 Dermatitis cruris pustulosa et atrophicans
Kaimal, S., DęSouza, M., Kumari, R.
Indian Journal of Dermatology, Venereology and Leprology. 2009; 75(4): 348-355
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow